Ionis Pharmaceuticals grants 3,399 RSUs to director

Q: What equity award did Ionis Pharmaceuticals (IONS) grant to Peter N Reikes?

Ionis Pharmaceuticals granted director Peter N Reikes 3,399 Restricted Stock Units on July 15, 2026. Each unit provides a contingent right to receive one share of Ionis common stock or its equivalent cash value, subject to a multi-year vesting schedule through July 15, 2029.

Q: How do the Ionis Pharmaceuticals (IONS) RSUs for Peter N Reikes vest over time?

The 3,399 RSUs granted to Peter N Reikes vest in three equal annual installments. The first installment vests on July 15, 2027, with additional installments on the following two anniversaries, so the award is fully vested on July 15, 2029.

Q: How many Ionis Pharmaceuticals (IONS) RSUs does Peter N Reikes hold after this grant?

Following the July 15, 2026 grant, Peter N Reikes holds 3,399 Restricted Stock Units directly. According to the grant terms, the RSUs are vested as to 0 shares on the grant date, with vesting commencing in 2027 and finishing in 2029.

Reikes Peter N reported acquisition or exercise transactions in this Form 4 filing.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Reikes Peter N reported acquisition or exercise transactions in this Form 4 filing.

Ionis Pharmaceuticals Inc granted director Peter N Reikes 3,399 Restricted Stock Units on July 15, 2026 under its Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. The RSUs vest in three equal annual installments starting July 15, 2027 and will be fully vested on July 15, 2029. Following this award, Reikes holds 3,399 RSUs directly, all unvested as of the grant date.

Insider Trade Summary

Grant/Award: 3,399 shares

Grant/Award 1 txn

Insider Reikes Peter N

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit ^{F1, F2}	3,399	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 3,399 contracts (Direct)

Footnotes (2)

F1. Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
F2. Grant on July 15, 2026 to reporting person of Restricted Stock Unit Award under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in three equal annual installments, the first installment vesting on July 15, 2027. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 15, 2029. The RSU is vested as to 0 shares on July 15, 2026.

Key Figures

RSUs granted: 3,399 Restricted Stock Units Underlying common shares: 3,399 shares of Common Stock Vesting installments: 3 equal annual installments +2 more

5 metrics

RSUs granted 3,399 Restricted Stock Units Grant to director Peter N Reikes on July 15, 2026

Underlying common shares 3,399 shares of Common Stock Each RSU represents a contingent right to one share or its cash value

Vesting installments 3 equal annual installments First installment vests on July 15, 2027

Full vesting date July 15, 2029 RSU award shall be fully vested on this date

Post-grant RSU holdings 3,399 Restricted Stock Units Total direct RSU holdings following the reported transaction

Key Terms

Restricted Stock Unit, contingent right, Amended and Restated 2002 Non-Employee Directors' Stock Option Plan

3 terms

Restricted Stock Unit financial

"Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

contingent right financial

"represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value"

Amended and Restated 2002 Non-Employee Directors' Stock Option Plan financial

"Award under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity award did Ionis Pharmaceuticals (IONS) grant to Peter N Reikes?

Ionis Pharmaceuticals granted director Peter N Reikes 3,399 Restricted Stock Units on July 15, 2026. Each unit provides a contingent right to receive one share of Ionis common stock or its equivalent cash value, subject to a multi-year vesting schedule through July 15, 2029.

How do the Ionis Pharmaceuticals (IONS) RSUs for Peter N Reikes vest over time?

The 3,399 RSUs granted to Peter N Reikes vest in three equal annual installments. The first installment vests on July 15, 2027, with additional installments on the following two anniversaries, so the award is fully vested on July 15, 2029.

When will the Ionis Pharmaceuticals (IONS) RSUs granted to Peter N Reikes be fully vested?

The RSU award to Peter N Reikes is scheduled to be fully vested on July 15, 2029. Vesting occurs in three equal annual installments beginning July 15, 2027, and no shares were vested as of the grant date, July 15, 2026.

What does each Restricted Stock Unit represent in the Ionis (IONS) grant to Peter N Reikes?

Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. Upon vesting, the RSUs will be settled in whole shares of common stock or cash, as may be determined by the company.

How many Ionis Pharmaceuticals (IONS) RSUs does Peter N Reikes hold after this grant?

Following the July 15, 2026 grant, Peter N Reikes holds 3,399 Restricted Stock Units directly. According to the grant terms, the RSUs are vested as to 0 shares on the grant date, with vesting commencing in 2027 and finishing in 2029.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 07/17/2026 - 05:13 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reikes Peter N

(Last)

(First)

(Middle)

2855 GAZELLE COURT

(Street)

CARLSBAD

CALIFORNIA

92010

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit	$0.0⁽¹⁾	07/15/2026		A		3,399		⁽²⁾	⁽²⁾	Common Stock	3,399	$0.0	3,399	D

Explanation of Responses:

1. Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

2. Grant on July 15, 2026 to reporting person of Restricted Stock Unit Award under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in three equal annual installments, the first installment vesting on July 15, 2027. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 15, 2029. The RSU is vested as to 0 shares on July 15, 2026.

	By: Patrick R. O'Neil, attorney-in-fact For: Peter N. Reikes	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR